// App-Quantinova.ai

653 : Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.

Researchers

Presenter

  • Herbert Hurwitz

Principal Investigators

  • John D. Hainsworth

  • Charles Swanton

  • Edith A. Perez

  • Christopher Sweeney

  • Howard A. Burris

  • David Spigel

  • Funda Meric-Bernstam

  • Donald K Strickland

  • Larry Leon

  • Melissa Brammer

  • Mary Stanley Beattie

  • Ron Bose

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Sarah Cannon Research Institute and University College London Cancer Institute, London, United Kingdom

  • Mayo Clinic, Jacksonville, FL

  • Dana-Farber Cancer Institute, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Genentech, Inc., South San Francisico, CA

  • Washington University School of Medicine, St. Louis, MO

Locations

  • United States

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • Vemurafenib

  • Pertuzumab

  • Vismodegib

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT02091141

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved